In a surprising study, researchers at the University of California, Irvine, led by Professor Thomas Ahlering found that in a sample of carefully selected men who had low-risk prostate cancer and who had surgery, testosterone replacement therapy significantly lowered their risk for having a prostate cancer recurrence!
The practice of “surprising” patients with unexpected, exorbitant bills needs to stop and insurance companies need to become responsible for reasonable out of network medical expenses
The ProVent Trial is a phase 3 trial for men on active surveillance. The trial is designed to evaluate the efficacy of Provenge for men who are still at one of the earliest stages of the disease, active surveillance. The trial’s goal is to assess the ability of Provenge to reduce the risk of disease progression in men on Active Surveillance.
In a presentation at the European Association of Urology Congress in Barcelona, Spain there was a report that showed that prostate cancer patients who had high levels of neuroticism (a broad personality trait in which a person experiences the world as distressing, threatening, and unsafe place) had significantly more adverse events following surgery, including sexual dysfunction and urinary incontinence. The data was created from a survey of almost 1,000 men
One question we often hear at Cancer ABCs is about the efficacy of laser targeted removal of cancerous tissue from the prostate gland as opposed to removing the entire gland. Recently described research from Dr. Eric Walser who is at The University of Texas Medical Branch at Galveston has shown that selectively destroying cancerous prostate tissue inside of the prostate gland can be as effective as the removal of the entire prostate gland.
If you are an African American man and have been diagnosed with prostate cancer, you can help us better understand the significant differences that African American men have in risk factors for prostate cancer.
Recently released and unexpected findings have been announced, contrary to previous understandings, black men who received primary radiation therapy to treat their prostate cancer had lower rates of biochemical cancer recurrence than white men. They also had a lower rate of developing distant metastasis. These findings are from data coming from the randomized RTOG trials and were reported at the American Society of Radiation Oncology by Daniel Spratt, MD, of the University of Michigan in Ann Arbor.
Making this finding even more interesting is the finding that Black men do better when they receive Provenge than white men
Both of these findings point out that there are likely differences in the underlying prostate cancer disease between Black and White men. However, this conclusion does not negate the fact that Black men have less access to treatment than White men, a fact that needs to be corrected, especially given the circumstances indicated in these two conclusions that Black men do well when given treatment.
By Joel T. Nowak
Researchers have found evidence that is having an early supper or leaving at least two hours before going to bed are associated with a lower risk of developing breast and prostate cancer!
A recent study, published in the Lancet Oncology compared robotic to open prostate cancer surgery (prostatectomy). The study found that over a two-year period both forms of surgery produced equivalent results for preserving erectile function and urinary continence. However, there were some differences.
There are a number of items of news about state expansion of Medicaid, Family Leave and some attempts by certain states to screw their citizens who have cancer or chronic illnesses go around the federal medical insurance laws by
How radiation is delivered as a primary treatment for prostate cancer therapy has been changing, mostly since 2017. The change involves two different items, one the method of delivery of the radiation and the increasing use of a newly developed “safety” product that lowers the adverse side effects of the radiation treatment.
In a large study, it was found that men of African American (AA) descent who are candidates for active surveillance are not at an increased risk of being upstaged or upgraded at surgery compared to other men.
The men who received dose escalated radio therapy had less need for secondary therapies, but they did not have any survival advantage.
Researchers have concluded that high dose radiation therapy as a primary therapy does not improve survival. However, it does reduce PSA failures and the need to use salvage therapy.
A retrospective study reported about the benefits and late toxicity following an injection of a hydrogel spacer (HS) between the prostate and rectum for men treated with radiotherapy.
Having a very low PSA does not indicate that your prostate cancer is not aggressive.
Etna Insurance approves the use of SpaceOAR to protect men during their radiation treatments.
At last year’s American Society of Clinical Oncology GU Conference (ASCO-GU) researchers reported that men who took at least three aspirin tablets a week reduced their risk of developing or dying from advanced prostate cancer.
The European Union has recently placed some restrictions on the use of the MRI contrast agent Gadolinium.
The American Society of Clinical Oncology (ACSO), has declared that people drinking alcoholic drinks face a significantly increased risk of developing cancer(s).